LEXICON PHARMACEUTICALS, INC. |
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 1.77 USD | 0.00% |
|
-5.35% | +15.69% |
Days
Hours
Minutes
Seconds
-40%
on all our subscriptions*
Exceptional extension!
Take advantage of the offer
* See conditions on site
Financials (USD)
| Sales 2024 * | 24.2M | Sales 2025 * | 83.79M | Capitalization | 640M |
|---|---|---|---|---|---|
| Net income 2024 * | -200M | Net income 2025 * | -201M | EV / Sales 2024 * | 26.4 x |
| Net cash position 2024 * | - | Net cash position 2025 * | - | EV / Sales 2025 * | 7.64 x |
| P/E ratio 2024 * |
-2.31
x | P/E ratio 2025 * |
-2.58
x | Employees | 285 |
| Yield 2024 * |
-
| Yield 2025 * |
-
| Free-Float | 98.44% |
More Fundamentals
* Assessed data
More news
Latest transcript on Lexicon Pharmaceuticals, Inc.
More recommendations
More press releases
More news
| 1 week | -5.35% | ||
| Current month | +14.94% | ||
| 1 month | +7.27% | ||
| 3 months | -33.21% | ||
| 6 months | +50.00% | ||
| Current year | +15.69% |
1 week
1.76
2.04
1 month
1.482.04
Current year
1.243.73
1 year
0.923.73
3 years
0.926.33
5 years
0.929.65
10 years
0.9219.62
| Managers | Title | Age | Since |
|---|---|---|---|
Lonnel Coats
CEO | Chief Executive Officer | 58 | 14-07-06 |
Jeffrey Wade
DFI | Director of Finance/CFO | 59 | 98-12-31 |
Craig Granowitz
CTO | Chief Tech/Sci/R&D Officer | 60 | 21-08-01 |
| Members of the board | Title | Age | Since |
|---|---|---|---|
Robert Lefkowitz
BRD | Director/Board Member | 80 | 01-01-31 |
Ray Debbane
CHM | Chairman | 69 | 07-07-31 |
| Director/Board Member | 65 | 07-08-27 |
| Name | Weight | AuM | 1st Jan change | Investor Rating |
|---|---|---|---|---|
| 0.00% | 9 M€ | +11.21% | - | |
| 0.00% | 1,487 M€ | +9.49% | - |
| Date | Price | Change | Volume |
|---|---|---|---|
| 24-05-20 | 1.77 | 0.00% | 2,576,152 |
| 24-05-17 | 1.77 | -3.80% | 1,847,436 |
| 24-05-16 | 1.84 | -5.15% | 1,616,085 |
| 24-05-15 | 1.94 | +1.04% | 1,470,630 |
| 24-05-14 | 1.92 | +2.67% | 1,659,383 |
Delayed Quote Nasdaq, May 20, 2024 at 04:00 pm EDT
More quotes
Lexicon Pharmaceuticals, Inc. is a biopharmaceutical company. The Company is focused on the discovery, development, and commercialization of pharmaceutical products for the treatment of human disease. The Company pipeline includes INPEFA (sotagliflozin), LX9211, and LX9851. Sotagliflozin is an orally delivered small molecule compound that is being developed for the treatment of heart failure and type I diabetes, and type II diabetes mellitus, chronic kidney disease and other cardiovascular risk factors. LX9211 is an orally delivered small molecule compound that is being developed for the treatment of neuropathic pain. The Company is conducting a Phase II clinical trial of LX9211 in diabetic peripheral neuropathic pain and a second Phase II clinical trial of LX9211 in post-herpetic neuralgia. The Company is conducting preclinical development of LX9851, an orally delivered small molecule drug candidate, as a treatment for obesity and tool for weight management.
Calendar
2024-07-31
- Q2 2024 Earnings Release (Projected)
Related indices
Trading Rating
Investor Rating
ESG Refinitiv
C-
Sell
Buy
Mean consensus
OUTPERFORM
Number of Analysts
5
Last Close Price
1.77
USD
Average target price
5.25
USD
Spread / Average Target
+196.61%
EPS Revisions
| 1st Jan change | Capi. | |
|---|---|---|
| +15.69% | 640M | |
| +9.58% | 115B | |
| +12.41% | 107B | |
| -3.55% | 21.6B | |
| -12.38% | 22.31B | |
| -6.91% | 19.19B | |
| -3.35% | 18.23B | |
| -38.57% | 17.62B | |
| +7.51% | 14.26B | |
| +35.67% | 12.37B |
- Stock Market
- Equities
- LXRX Stock